Published online before print July 28, 2008, doi: 10.1161/CIRCULATIONAHA.108.784785
(Circulation. 2008;118:731-742.)
© 2008 American Heart Association, Inc.
Vascular Medicine |
Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction
From the Department of Geriatrics and Vascular Medicine (A.K., K.S.), Life Science and Bioethics Research Center (A.K., M.O., M.T., M.Y.), and Department of Biosystem Regulation, Institute of Biomaterials and Bioengineering (H.A.), Tokyo Medical and Dental University, Tokyo, Japan; Institute of Environmental Science for Human Life, Ochanomizu University, Bunkyo, Tokyo, Japan (M.T.); and Department of Nutrition, Harvard School of Public Health, and Department of Medicine, Harvard Medical School and Brigham & Women’s Hospital, Boston, Mass (F.M.S.).
Correspondence to Akio Kawakami or Masayuki Yoshida, Geriatrics and Vascular Medicine or Life Science and Bioethics Research Center, Tokyo Medical and Dental University, 1–5–45 Yushima, Bunkyo-ku, Tokyo, 1138519 Japan. E-mail kawakami.vasc{at}tmd.ac.jp or masa.vasc@tmd.ac.jp
Received December 31, 2007; accepted May 28, 2008.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Apolipoprotein CIII (apoCIII) is a component of some triglyceride-rich very-low-density and low-density lipoprotein and is elevated in dyslipidemia with insulin resistance and the metabolic syndrome. We previously reported that apoCIII directly activates proinflammatory and atherogenic signaling in vascular endothelial cells through protein kinase C-β (PKCβ). Because PKCβ impairs the response of vascular endothelial cells to insulin, we tested the hypothesis that apoCIII affects insulin signaling in vascular endothelial cells and its function in vitro and in vivo.
Methods and Results— ApoCIII inhibited insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), decreasing phosphatidylinositol 3-kinase (PI3K)/Akt activation in human umbilical vein endothelial cells. These effects of apoCIII led to reduced endothelial nitric oxide synthase (eNOS) activation and NO release into the media. ApoCIII activated PKCβ in human umbilical vein endothelial cells, resulting in IRS-1 dysfunction via serine phosphorylation. ApoCIII also activated mitogen-activated protein kinase through PKCβ. The impaired insulin signaling was restored by PKCβ inhibitor or MEK1 inhibitor. ApoCIII-rich very-low-density lipoprotein and apoCIII impaired insulin signaling in the aorta of C57BL/6J mice and in human umbilical vein endothelial cells, which was recovered by PKCβ inhibitor. They also inhibited endothelium-dependent relaxation of the aortas of C57BL/6J mice. In summary, apoCIII in very-low-density lipoprotein impaired insulin stimulation of NO production by vascular endothelium and induced endothelial dysfunction in vivo. This adverse effect of apoCIII was mediated by its activation of PKCβ, which inhibits the IRS-1/PI3K/Akt/eNOS pathway.
Conclusion— Our results suggest that apoCIII is a crucial link between dyslipidemia and insulin resistance in vascular endothelial cells with consequential deleterious effects on their atheroprotective functions.
Key Words: apolipoproteins • endothelium • hyperlipoproteinemia • insulin • nitric oxide synthase
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Apolipoprotein (apo) CIII is a small protein that resides in multiple copies on the surface of very-low-density lipoprotein (VLDL) and, to a lesser extent, low-density lipoprotein (LDL). It has been reported that apoCIII inhibits clearance from plasma of VLDL and LDL.1–3 Thus, apoCIII causes accumulation in plasma of atherogenic remnant lipoproteins and LDL rich in apoCIII, triglycerides, and cholesterol, which are prominent in diabetic and atherogenic dyslipidemia.4–7 Plasma levels of apoCIII containing VLDL and LDL predict risk of cardiovascular disease.4,8 The association of apoCIII with cardiovascular disease has been commonly attributed to its inhibitory effect on VLDL and LDL clearance, prolonging the plasma residence time of atherogenic remnant lipoproteins. Although this is undoubtedly true in part, we recently reported that apoCIII-rich VLDL does not have a longer residence time than its apoCIII-free counterparts9 because slow clearance is balanced by rapid lipolytic conversion to LDL, suggesting that the correlation between apoCIII and risk of coronary heart disease in population studies may be attributable in part to the direct involvement of apoCIII in atherogenesis. We recently showed that apoCIII has direct proinflammatory, atherogenic effects on vascular cells. ApoCIII activates monocytes and endothelial cells to enhance their adhesive interactions in atherosclerosis.10,11
Editorial p 702
Clinical Perspective p 742
Endothelial dysfunction is regarded as a causal factor in the initiation and development of cardiovascular disease, including hypertension and atherosclerosis.12,13 It is characterized by the reduced bioavailability of the signaling molecule nitric oxide (NO), which has potent vasodilatory and antiatherosclerotic properties.14 Vascular endothelium is a target tissue of insulin, and insulin resistance exists at the level of vascular endothelial cells.15,16 Insulin promotes bioavailability of NO by activating the signaling pathway involving the insulin receptor (IR), IR substrate-1 (IRS-1), phosphatidylinositol 3-kinase (PI3K), and Akt, which leads to the activation of endothelial NO synthase (eNOS).15 Insulin resistance and subsequent hyperinsulinemia also stimulate secretion of a potent vasoconstrictor endothelin-1 (ET-1) through mitogen-activated protein (MAP) kinase independently of PI3K-dependent signaling, which also contributes to endothelial dysfunction.17
Endothelial dysfunction is often seen in dyslipidemia and the metabolic syndrome,18 and the apoCIII level is high in these morbid conditions.6,7 ApoCIII is produced mainly in the liver, and its promoter has a negative insulin response element, which may account for the link between the impaired insulin action in hepatocytes and high apoCIII level.19 In the periphery, it is possible that reverse causation may be operative, involving apoCIII and insulin action, because protein kinase C-β (PKCβ) inhibits insulin action in endothelial cells20 and apoCIII activates PKCβ in the same cells.11 Thus, we tested the hypothesis that apoCIII itself impairs insulin signaling in endothelial cells, which results in diminished NO production. This hypothesis would add to the mechanisms by which apoCIII contributes to atherosclerosis and link dyslipidemia with vascular endothelial dysfunction.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cell Culture and Reagents
Human umbilical vein endothelial cells (HUVECs) were purchased from Clonetics Corp (San Diego, Calif) and cultured as previously described.11 HUVECs at passage 2 to 3 were used for the assays. Apolipoproteins were purified from human plasma with high-performance liquid chromatography and immunoaffinity column chromatography (Academy Biomedical Co, Inc, Houston, Tex). Endotoxin levels in apolipoproteins, measured with a Limulus amebocyte lysate chromogenic test (Associates of Cape Cod, East Falmouth, Mass), were <0.03 EU/mL. Free fatty acid (FFA) levels in apolipoproteins determined enzymatically were <20 nmol/L, which is much lower than reported to inhibit insulin signaling in endothelial cells.21 Antiapolipoprotein antibodies were purchased from Academy Biomedical Company, Inc. PD98059, wortmannin, and PKCβ-specific inhibitor [3-(1-(3-Imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione] were purchased from Calbiochem (San Diego, Calif). Insulin was purchased from Wako (Tokyo, Japan).
Lipoprotein Preparation
Blood was drawn in tubes containing EDTA from 10 healthy volunteers after 12 hours of fasting. The subjects were not taking cardiovascular medications, antioxidants, or estrogen. VLDL (d<1.006) with apoCIII (VLDL CIII+) or without apoCIII (VLDL CIII–) was isolated from plasma as described previously.10 The protocol of this study complied with the guidelines for the conduct of research involving human subjects by the Committee on Human Research at Tokyo Medical and Dental University. Apolipoprotein levels in VLDL preparations were determined by ELISA as described previously.4 Triglyceride levels in VLDL preparations were determined enzymatically. Endotoxin levels in VLDL preparations were <0.03 EU/mL.
Immunoblotting
After being cultured for 24 hours in the serum-deprived medium without albumin, HUVECs were incubated with apoCIII or VLDL CIII+ and then stimulated with insulin. Total lysate and the membrane fraction of the cell lysate were prepared as described previously.11 Lysate was assayed with immunoblotting using anti–phospho-Akt antibody, anti-Akt antibody, anti–phospho-PI3K antibody, anti-PI3K antibody, anti–phospho-IRS-1 (Tyr989) antibody, anti–IRS-1 antibody, anti–phospho-eNOS antibody, anti-eNOS antibody, anti–phospho-IRβ antibody, anti-IRβ antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif), anti–phospho-IRS-1 (Ser616) antibody (Abcam, Inc, Cambridge, Mass), anti–phospho-IRS-1 (Ser612) antibody (Cell Signaling Technology, Inc, Danvers, Mass), anti–phospho-ERK1/2 antibody, anti-ERK1/2 antibody, anti–phospho-JNK antibody, and anti-JNK antibody (New England Biolabs, Beverly, Mass). Activation of PKC was assessed by detecting the membrane-bound protein that translocated from cytosol fraction using antibodies to anti-PKCβI antibody and anti-PKCβII antibody (Santa Cruz).
Quantification of NO and ET-1
NO levels in the culture media or plasma were measured with the Nitric Oxide Colorimetric Assay Kit (Biomol, Plymouth Meeting, Pa) following the manufacturer’s instructions. ET-1 levels in the culture media were measured with an ELISA kit (R&D Systems, Minneapolis, Minn).
In Vivo ApoCIII Stimulation
Please see the Materials and Methods section of the online Data Supplement.
Isometric Tension Measurements
Please see supplementary Materials and Methods section.
Statistical Analysis
Results are given as mean±SD. Data were analyzed with an unpaired t test or 2-way ANOVA, with values of P<0.05 considered significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
ApoCIII Inhibits Insulin-Stimulated IRS-1 Tyrosine Phosphorylation in HUVECs
On insulin stimulation, IRS-1 is tyrosine phosphorylated by the IR to activate PI3K/Akt in vascular endothelial cells.17 We found that exposing HUVECs to apoCIII before insulin treatment blocked this established effect of insulin in a concentration-dependent manner at as early as 30 minutes of exposure (Figure 1A and 1B). Therefore, subsequent experiments used apoCIII at 100 µg/mL for 30 minutes unless otherwise indicated. ApoCIII did not affect the expression of IRβ or insulin-induced IRβ phosphorylation in HUVECs, suggesting that apoCIII affects insulin signaling downstream of IR (Figure 1C). Anti-apoCIII antibody, but not isotype-matched IgG, completely restored insulin-induced IRS-1 tyrosine phosphorylation (supplemental Figure IA).
|
ApoCIII Inhibits Insulin-Stimulated PI3K/Akt and eNOS Activation in HUVECs
PI3K and Akt are sequentially activated downstream of IRS-1, which in turn activates effector molecules in endothelial cells such as eNOS. ApoCIII attenuated insulin-induced phosphorylation of PI3K/Akt in a concentration-dependent manner (Figure 2A and 2B). ApoCIII attenuated insulin-stimulated eNOS activation(Figure 2C) and NO release into the culture media in a concentration-dependent manner (Figure 2D). Wortmannin, a PI3K inhibitor, abolished insulin-induced eNOS activation and NO release into the culture media. ApoCIII did not affect the expression of eNOS in HUVECs.
|
ApoCIII Activates PKCβ in HUVECs
Various isoforms of PKC mediate inflammation and other cellular events in atherosclerosis. Activation of PKC in endothelial cells and vascular tissue inhibits insulin-induced activation of eNOS, leading to impaired vasodilation.20 We recently showed that apoCIII in VLDL activates PKC
in monocytes and PKCβ in vascular endothelial cells, in which selective inhibition of either PKC isoform abolished apoCIII-induced upregulation of adhesion molecules.10,11 Moreover, we previously showed that remnant lipoproteins that are rich in apoCIII activate PKC and PKCβ in human monocytic cells and PKC and PKC
in rat aortic smooth muscle cells.22,23 We therefore tested the hypothesis that apoCIII inhibits insulin responses in vascular endothelial cells by activating PKCβ. ApoCIII increased membrane-bound PKCβII (Figure 3A), indicating its activation. ApoCIII minimally affected PKCβI activation. Anti-apoCIII antibody, but not isotype-matched IgG, completely abolished apoCIII-induced PKCβII activation (supplemental Figure IB). A PKCβ-specific inhibitor attenuated the inhibitory effect of apoCIII on eNOS activation and NO release into the culture media (Figure 3B and 3C). These results demonstrate the central role of PKCβII in impaired insulin signaling induced by apoCIII.
|
ApoCIII Activates MAP Kinase in HUVECs
Insulin also activates the small GTP binding protein Ras, which then initiates a phosphorylation cascade responsible for growth, mitogenesis, and ET-1 production involving the sequential activation of Raf, MEK, and ERK.17 We examined whether apoCIII affects insulin-induced ERK activation in endothelial cells. ApoCIII induced phosphorylation of ERK and augmented insulin-induced ERK activation (Figure 4A). A PKCβ-specific inhibitor partially reversed apoCIII-induced ERK activation (Figure 4B). Andreozzi et al24 reported that endothelial dysfunction is mediated through activation of JNK or ERK. Recent studies reported that ERK and PKC isoforms induce Ser616 phosphorylation of IRS-1.25 It is known that serine phosphorylation of IRS-1 inhibits its ability to be tyrosine phosphorylated by IR and to bind and activate PI3K. We tested the possibility that impaired insulin-stimulated IRS-1 function is associated with increased serine phosphorylation induced by PKCβ or ERK. As shown in Figure 4C, apoCIII induced Ser616 phosphorylation of IRS-1. ApoCIII-induced Ser616 phosphorylation of IRS-1 was blocked by PKCβ-specific inhibitor and partially reversed by PD98059, an MEK1-specific inhibitor. PKCβ-specific inhibitor completely and PD98059 partially restored Tyr989 phosphorylation of IRS-1 (Figure 4D). PD98059 also partially reversed the inhibitory effects of apoCIII on NO release (Figure 4E), suggesting the involvement of ERK in this process. In contrast, apoCIII did not activate JNK or p38 MAP kinase in endothelial cells, and apoCIII-induced Ser616 phosphorylation of IRS-1 was not affected by their inhibitors (data not shown). Finally, we confirmed that apoCIII increased the ET-1 level in the culture media, which was abolished by PKCβ-specific inhibitor and PD98059 (Figure 4F). These results indicate that apoCIII may cause or augment an imbalance between vasodilator and vasoconstrictor actions of insulin through pathway-specific insulin resistance.13,17
|
ApoCIII Inhibits Insulin Signaling in the Aortas of C57BL/6J Mice
We next tested whether apoCIII would affect an insulin-stimulated eNOS pathway in vivo. Human apoCIII level in the plasma was 78±18 µg/mL after 30 minutes of apoCIII (500 µg per body) injection into C57BL/6J mice (mouse apoCIII level in the plasma was 38±12 and 33±14 µg/mL before and after apoCIII injection, respectively). Short-time stimulation with apoCIII did not significantly change fasting plasma triglycerides, FFA, and insulin levels (triglycerides, 52±18 and 61±19 mg/dL; FFA, 0.89±0.12 and 0.96±0.20 mmol/L; insulin, 178±18 and 167±21 pmol/L before and after 30 minutes, respectively). However, apoCIII activated PKCβII and ERK in the aortas of C57BL/6J mice at 500 µg per body (Figure 5A and 5B). ApoCIII stimulated Ser612 phosphorylation of IRS-1 (orthologous to Ser616 in human IRS-1), which was attenuated by a PKCβ-specific inhibitor (Figure 5C). ApoCIII reduced the insulin effect on tyrosine phosphorylation of IRS-1 and eNOS in the aorta (Figure 5D and 5E). PKCβ-specific inhibitor reversed these inhibitory effects of apoCIII. It also restored the NO level in the plasma reduced by apoCIII (Figure 5F).
|
VLDL CIII+ Inhibits Insulin Signaling in the Aortas of C57BL/6J Mice
ApoCIII is a component of some VLDL and other lipoproteins in blood. We tested whether VLDL CIII+ or VLDL CIII– affects the insulin-stimulated NOS pathway in vivo. Triglycerides in VLDL CIII+ and VLDL CIII– were 10.3±2.8 and 3.3±0.8 µg/µg apoB, respectively. ApoCIII in VLDL CIII+ was 0.80±0.14 µg/µg apoB. Lipid and insulin after 30 minutes of VLDL injection were as follows: triglycerides, 75±18 and 125±38 mg/dL; FFA, 1.51±0.25 and 1.63±0.35 mmol/L; and insulin, 190±34 and 184±24 pmol/L VLDL CIII– and VLDL CIII+, respectively. There were no significant differences in plasma FFA and insulin levels between the 2 groups. Human apoCIII level in plasma was 72±15 µg/mL after 30 minutes of VLDL CIII+ injection (mouse apoCIII level in the plasma was 35±18 and 31±15 µg/mL before and after VLDL CIII+ injection, respectively). Human VLDL CIII+ stimulated PKCβII activation and Ser612 phosphorylation of IRS-1 in the aorta of C57BL/6J mice. In contrast, VLDL CIII– had minimal effect on these processes (Figure 6A and 6B). PKCβ-specific inhibitor partially inhibited Ser612 phosphorylation of IRS-1 by VLDL CIII+ (Figure 6C) and restored insulin-stimulated Tyr989 phosphorylation of IRS-1 in the aortas (Figure 6D) and NO release into the plasma (Figure 6E). VLDL CIII– had minimal effect on insulin-induced NO release.
|
We confirmed the effect of VLDL CIII+ in vitro. Pretreatment of VLDL CIII+ with an anti-apoCIII function-blocking antibody attenuated PKCβII activation by VLDL CIII+ in HUVECs (supplemental Figure IC). VLDL CIII+ also is rich in apoCI and apoE (0.23±0.08 and 0.35±0.05 µg/µg apoB, respectively) compared with VLDL CIII–. However, anti-apoCI and anti-apoE antibodies had minimal effects on PKCβII activation (supplemental Figure IC). Both apoCI and apoE did not activate PKCβII of HUVECs or inhibit insulin-induced NO release into the culture media at 100 µg/mL (supplemental Figure IIA and IIB). They also did not activate PKCβII of the aorta of C57BL/6J mice or inhibit NO release into the plasma (supplemental Figure IIC and IID). Thus, acute administration of apoCIII-rich VLDL impaired insulin signaling in the aortas of C57BL/6J mice, suggesting the pivotal role of apoCIII itself and PKCβII in this process.
ApoCIII Inhibits Endothelium-Dependent Relaxation in the Aortas of C57BL/6J Mice
We finally determined whether apoCIII induces endothelial dysfunction in vivo using isometric tension measurements. In preliminary experiments, carbachol-induced relaxation of the aortic ring of C57BL/6J mice was abolished by the NOS inhibitor L-NG-nitro arginine or removal of its endothelium, suggesting that the measurement reflects vascular endothelial cell– and NO-dependent relaxation (supplemental Figure III). ApoCIII stimulation significantly impaired endothelium-dependent relaxation of the isolated aortic rings of C57BL/6J mice, which was recovered by PKCβ-specific inhibitor (Figure 7A). VLDL CIII+ also impaired endothelium-dependent relaxation. In contrast, VLDL CIII– had minimal effect on it (Figure 7B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study reports for the first time that apoCIII and apoCIII-rich VLDL cause insulin resistance in vascular endothelial cells. We provide evidence that exposure of vascular endothelial cells to apoCIII resulted in inhibition of insulin-stimulated eNOS activity and NO production. Clinical studies revealed that apoCIII is associated with insulin resistance in subjects with the metabolic syndrome or type 2 diabetes.7 It is reported that insulin resistance in hepatocytes causes apoCIII overproduction through deregulation of Foxo1.26,27 Our findings suggest that increased serum apoCIII is not just a clinical manifestation of insulin resistance but a causative factor for the development of insulin resistance in endothelium.
Insulin action in the endothelium is mediated by the signaling pathway involving IRS-1/PI3K/Akt that leads to increased eNOS activity (the eNOS pathway).14 PKCs play an important role in the development of insulin resistance by inhibiting this process. Naruse et al20 reported that activation of PKCβ in endothelial cells and vascular tissue inhibits insulin-induced Akt activation and subsequent eNOS activation. We recently showed that apoCIII in VLDL activates PKCβ in vascular endothelial cells and induces vascular cell adhesion molecule-1 upregulation.11 Selective inhibition of PKCβ abolished this process. Moreover, remnant lipoproteins that are rich in apoCIII activate PKCs in human monocytic U937 cells and rat aortic smooth muscle cells.22,23 In the present study, apoCIII activated PKCβII in HUVECs. ApoCIII-induced serine phosphorylation of IRS-1 was dependent on PKCβ. Indeed, a PKCβ-specific inhibitor reversed the inhibitory effect of apoCIII on this insulin signaling. Several PKC isoforms, including PKCβII, negatively regulate IRS-1 function by serine phosphorylation.25,28 These results indicate a central role of PKCβII in impaired insulin signaling induced by apoCIII. Although the mechanism(s) by which apoCIII activates PKCs in endothelial cells or monocytes remain to be fully elucidated, we recently reported that apoCIII activates PKCs through a pertussis toxin–sensitive G protein and phospholipase C in THP-1 cells,29 suggesting that a distinct pathway or receptor may be involved in this process. Further studies are needed to elucidate the specific apoCIII signaling pathways.
This study also identified PKCβ as the key molecule that regulates the MAP kinase and eNOS pathways. Insulin activates the small GTP binding protein Ras, which then initiates a phosphorylation cascade involving Raf, MEK, and ERK. We previously reported that apoCIII-rich remnant lipoproteins stimulate the proliferation of vascular smooth muscle cells through PKC-mediated MAP kinase activation.23 Recent reports suggest that there is crosstalk between the eNOS and MAP kinase pathways. Andreozzi et al24 reported that interleukin-6 impairs the vasodilator effects of insulin that are mediated by the eNOS pathway in endothelial cells through activation of JNK and ERK. These reports prompted us to examine whether apoCIII also would activate MAP kinase in HUVECs through its involvement in the eNOS pathway. We found that apoCIII itself activated ERK and augmented insulin-stimulated MAP kinase activation. The inhibition of this pathway partially reversed the effects of apoCIII on Ser616 phosphorylation of IRS-1, suggesting that MAP kinase contributes to the impairment of the eNOS pathway. Activated MAP kinase also stimulates secretion of ET-1 from endothelial cells. In accordance, we found that apoCIII increased ET-1 release. Thus, apoCIII may cause or augment an imbalance between vasodilator and vasoconstrictor actions of insulin through its distinctive signaling pathway (Figure 8).
|
We evaluated the results obtained in cultured endothelial cells in an in vivo model. Administration of apoCIII impaired insulin signaling in the aortas of C57BL/6J mice. Moreover, apoCIII impaired endothelium-dependent relaxation of aortic rings of C57BL/6J mice, suggesting that apoCIII induces endothelial dysfunction. ApoCIII-rich VLDL, but not apoCIII-deficient VLDL, exerted similar inhibitory effects, although these results reflect overall effects of apoCIII or apoCIII-rich VLDL on whole aorta, not on vascular endothelium alone. What should be noted here is that apoCIII-rich VLDL contains other apolipoproteins (eg, apoCI, E) and lipid moieties that are different from apoCIII-deficient VLDL.5,9 Thus, it is possible that apoCIII may not be the only component that accounts for the effects of apoCIII-rich VLDL. Moreover, apoCIII impairs catabolism of triglyceride-rich lipoproteins in vivo, which may modify other lipid parameters that affect insulin sensitivity of endothelial cells. However, considering the results of our experiments using apoCIII alone in vitro and in vivo and those using an anti-apoCIII function blocking antibody in vitro, we conclude that apoCIII in hypertriglyceridemic VLDL directly impairs insulin signaling in vascular endothelial cells, at least in part. Previous clinical studies have shown an acute and direct effect of hypertriglyceridemia on vascular endothelium. Acute hypertriglyceridemia induced by an oral fat load caused endothelial dysfunction in subjects with dyslipidemia30 and increased circulatory cellular adhesion molecules in healthy subjects.31 Further study is needed to clarify the involvement of apoCIII in this phenomenon.
ApoCIII impaired insulin signaling in vascular endothelial cells and caused endothelial dysfunction at 
100 µg/mL in vitro and in vivo. This concentration corresponds to the middle of the population range. However, it is in the upper part of the range for apoCIII in VLDL because apoCIII resides on not only apoB lipoproteins but also high-density lipoprotein. Indeed, epidemiological studies have shown a gradient of risk for apoCIII in apoB lipoproteins starting from a lower level, eg, 2 mg/dL, the first quartile.4 Thus, we believe that apoCIII affects endothelial cells at clinically relevant concentrations in the upper part of the population distribution, supporting the clinical relevance of the present study.
Studies using apoCIII transgenic mice provide a complex, as-yet unresolved, picture of apoCIII and insulin action. Human apoCIII transgenic mice had hypertriglyceridemia and high serum FFA levels but normal glucose tolerance and normal adipocyte responses to glucose.32,33 Another study reported that apoCIII transgenic mice showed impaired insulin secretion,34 which is consistent with apoCIII causing apoptosis in cultured pancreatic β cells.35 We also examined the effects of apoCIII on insulin response in other insulin-sensitive cells. ApoCIII had minimal effects on insulin signaling in 3T3L1 cells and HepG2 cells (data not shown). These findings suggest that the apoCIII effect on insulin signaling may be cell-type specific.
Endothelial dysfunction associated with hypertriglyceridemia has been understood from the traditional view that FFA and other lipid moieties in triglyceride-rich lipoproteins impair insulin action and/or endothelial dysfunction. However, our findings may add a new mechanism in which triglyceride-rich lipoproteins are carriers of a causal factor for it, ie, apoCIII, although this apoCIII mechanism is not exclusive of the lipid hypothesis. Our observations provide novel insights into a role for apoCIII as a key molecule that could link dyslipidemia with endothelial dysfunction in the metabolic syndrome.
|
Acknowledgments |
|---|
We thank Makoto Harada for technical assistance.
Sources of Funding
This study was supported by a grant-in-aid from Ministry of Education, Science and Technology (10178102); a grant-in-aid from the ONO Medical Research Foundation; a grant-in-aid from the Takeda Science Foundation; a grant-in-aid from the Mitsukoshi Health and Welfare Foundation; a grant-in-aid from the Uehara Memorial Foundation; and a Sakakibara Memorial research grant from the Japan Research Promotion Society for Cardiovascular Diseases.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986; 78: 1287–1295.[Medline] [Order article via Infotrieve]
2. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992; 90: 1889–1900.[Medline] [Order article via Infotrieve]
3. Aalto-Setala K, Weinstock P, Bisgaier C, Wu L, Smith J, Breslow J. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res. 1996; 37: 1802–1811.[Abstract]
4. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000; 102: 1886–1892.
5. Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res. 2001; 42: 1239–1249.
6. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res. 2003; 44: 2374–2381.
7. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab. 2004; 89: 3949–3955.
8. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997; 17: 715–722.
9. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res. 2007; 48: 1190–1203.
10. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006; 113: 691–700.
11. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006; 114: 681–687.
12. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
13. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007; 28: 463–491.
14. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002–2012.
15. Zeng G, Nystrom FH, Ravichandran LV, Cong L-N, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000; 101: 1539–1545.
16. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest. 2003; 111: 1373–1380.[CrossRef][Medline] [Order article via Infotrieve]
17. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113: 1888–1904.
18. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, Kodama Y, Mende A, Ichigi Y, Fujioka D, Saito Y, Kugiyama K. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis. 2005; 181: 321–327.[CrossRef][Medline] [Order article via Infotrieve]
19. Chen M, Breslow J, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res. 1994; 35: 1918–1924.[Abstract]
20. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, Jacobs JR, Clermont AC, Ueki K, Ohshiro Y, Zhang J, Goldfine AB, King GL. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006; 55: 691–698.
21. Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, Coselli JS, Shen YH. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes. 2006; 55: 2301–2310.
22. Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res. 2002; 91: 263–271.
23. Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M. Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation. 2003; 108: 2679–2688.
24. Andreozzi F, Laratta E, Procopio C, Hribal ML, Sciacqua A, Perticone M, Miele C, Perticone F, Sesti G. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol. 2007; 27: 2372–2383.
25. Greene MW, Ruhoff MS, Roth RA, Kim J-A, Quon MJ, Krause JA. PKCdelta-mediated IRS-1 Ser24 phosphorylation negatively regulates IRS-1 function. Biochem Biophys Res Commun. 2006; 349: 976–986.[CrossRef][Medline] [Order article via Infotrieve]
26. Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, Tse T, Jiang Y, Dong HH. PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab. 2007; 292: E421–E434.
27. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004; 114: 1493–1503.[CrossRef][Medline] [Order article via Infotrieve]
28. Ishizuka T, Kajita K, Natsume Y, Kawai Y, Kanoh Y, Miura A, Ishizawa M, Uno Y, Morita H, Yasuda K. Protein kinase C (PKC) beta modulates serine phosphorylation of insulin receptor substrate-1 (IRS-1)–effect of overexpression of PKCbeta on insulin signal transduction. Endocr Res. 2004; 30: 287–299.[CrossRef][Medline] [Order article via Infotrieve]
29. Kawakami A, Aikawa M, Nitta N, Yoshida M, Libby P, Sacks FM. Apolipoprotein CIII–induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler Thromb Vasc Biol. 2007; 27: 219–225.
30. Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappie S, Catapano AL. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab. 2004; 89: 2946–2950.
31. Mansoor MA, Seljeflot I, Arnesen H, Knudsen A, Bates CJ, Mishra G, Larsen TW. Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia. Clin Biochem. 2004; 37: 408–414.[CrossRef][Medline] [Order article via Infotrieve]
32. Reaven G, Mondon C, Chen Y, Breslow J. Hypertriglyceridemic mice transgenic for the human apolipoprotein C-III gene are neither insulin resistant nor hyperinsulinemic. J Lipid Res. 1994; 35: 820–824.[Abstract]
33. Amaral MEC, Oliveira HCF, Carneiro EM, Delghingaro-Augusto V, Vieira EC, Berti JA, Boschero AC. Plasma glucose regulation and insulin secretion in hypertriglyceridemic mice. Horm Metab Res. 2002; 34: 21–26.[CrossRef][Medline] [Order article via Infotrieve]
34. Salerno AG, Silva TR, Amaral MEC, Alberici LC, Bonfleur ML, Patricio PR, Francesconi EPMS, Grassi-Kassisse DM, Vercesi AE, Boschero AC, Oliveira HCF. Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice. Int J Obes. 2007; 31: 1586–1595.[CrossRef][Medline] [Order article via Infotrieve]
35. Juntti-Berggren L, Refai E, Appelskog I, Andersson M, Imreh G, Dekki N, Uhles S, Yu L, Griffiths WJ, Zaitsev S, Leibiger I, Yang SN, Olivecrona G, Jornvall H, Berggren PO. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci U S A. 2004; 101: 10090–10094.
|
Footnotes |
|---|
Guest Editor for this article was Donald Heistad, MD.
The online Data Supplement can be found with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.108.784785/DC1.
Related Article:
Circulation 2008 118: 697-698.
This article has been cited by other articles:
 |
|
 |
|
  S. Caron and B. Staels Apolipoprotein CIII: A Link Between Hypertriglyceridemia and Vascular Dysfunction? Circ. Res., December 5, 2008; 103(12): 1348 - 1350. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bobik Apolipoprotein CIII and Atherosclerosis: Beyond Effects on Lipid Metabolism Circulation, August 12, 2008; 118(7): 702 - 704. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||